The Wilms’ tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy

详细信息    查看全文

• 作者：Daniela Gallo ; Paolo Nicoli ; Chiara Calabrese ; Valentina Gaidano ; Jessica Petiti ; Valentina Rosso ; Elisabetta Signorino ; Sonia Carturan ; Giada Bot-Sartor ; Gisella Volpe ; Francesco Frassoni ; Giuseppe Saglio and Daniela Cilloni
• 刊名：Cancer Medicine
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：5
• 期：7
• 页码：1650-1653
• 全文大小：164K
• ISSN：2045-7634

文摘

The Wilms tumor gene WT1 is a useful marker of clonal hematopoiesis and it has been shown to be a good marker of residual disease and it reflects the response to therapy. Although myelofibrosis is characterized by mutations of JAK2 and calreticulin (CALR), these mutations are not useful to monitor response to therapy. In this study we demonstrated that in patients affected by myelofibrosis WT1 correlates with the International Prognostic Scoring System (IPSS) score at diagnosis. Furthermore WT1 is a good marker of response to JAK2 inhibitors especially for patients without blasts and for patients who develop anemia or thrombocytopenia not for progression but as therapy related toxicity. Finally, WT1 transcript reduction can mirror a benefit of therapy on the disease burden. This study demonstrated that WT1 is a good marker for monitoring the response to therapy in patients affected by myelofibrosis.